Fundraising FoxOcean Biomedical
OTC: OCEAProvidence, US · Founded 2019 · Delaware corporation
Find your way into Ocean Biomedical
Sign up to see every warm intro you have to Ocean Biomedical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ocean Biomedical team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ocean Biomedical is a biopharmaceutical company developing drugs for oncology, fibrosis, and infectious diseases by licensing technologies from academic research institutions including Brown University and Rhode Island Hospital. The company's pipeline includes monoclonal antibodies and small molecule candidates for non-small cell lung cancer, glioblastoma, idiopathic pulmonary fibrosis, and malaria, with preclinical programs anticipated to advance to clinical development.
Founders & leadership
Ocean Biomedical was founded in 2019 by Chirinjeev Kathuria,.
Reported raises · per SEC filings
Form D private placements$8.6M disclosed across 2 rounds · 2021–2023
▶$7.6MraisedJun 2023 · 1 investors · BiotechnologyRule 506(b)
- Jack A. EliasDirector
- William OwensDirector
- Jonathan KurtisDirector
- Michael PetersonDirector
- Robert SweeneyExecutive Officer
- Martin D. AngleDirector
- Inderjote KathuriaExecutive Officer
- Michelle BerreyDirector
- Gurinder KalraExecutive Officer
- Jerome RingoDirector
- Daniel BehrExecutive Officer
- Suren AjjarapuDirector
- Elizabeth NgExecutive Officer, Director
- Chirinjeev KathuriaDirector
- Offering amount
- $27M
- Amount sold
- $7.6M
- Minimum investment
- $7.6M
- Sales commissions
- $1.8M
- Proceeds to insiders
- $1.6M
- Placement agents
- Maxim Group LLC
- First sale
- May 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1MraisedApr 2021 · 27 investors · BiotechnologyRule 506(b)
- Chirinjeev Kathuria,Executive Officer, Director
- Elizabeth NgExecutive Officer, Director
- Jonathan HellerExecutive Officer
- Gurinder KalraExecutive Officer
- Amount sold
- $1M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Ocean Biomedical do?
- Ocean Biomedical is a biopharmaceutical company developing drugs for oncology, fibrosis, and infectious diseases by licensing technologies from academic research institutions including Brown University and Rhode Island Hospital. The company's pipeline includes monoclonal antibodies and small molecule candidates for non-small cell lung cancer, glioblastoma, idiopathic pulmonary fibrosis, and malaria, with preclinical programs anticipated to advance to clinical development.
- Who founded Ocean Biomedical?
- Ocean Biomedical was founded by Chirinjeev Kathuria, in 2019.
- How much funding has Ocean Biomedical raised?
- Ocean Biomedical has disclosed $8.6M raised across 2 rounds.
- Where is Ocean Biomedical headquartered?
- Ocean Biomedical is headquartered in Providence, US.